Analysis of the karyotype and desoxyribonucleic acid content of uterine myomas in premenopausal, menopausal, and gonadotropin-releasing hormone agonist-treated females.
OBJECTIVE
To correlate the cytogenetics and the DNA content in uterine myomas.


METHODS
Prospective study in treated and untreated females.


METHODS
Tertiary University Center.


METHODS
Premenopausal, menopausal, and GnRH-agonist (GnRH-a)-treated patients.


METHODS
Myomectomy or hysterectomy.


METHODS
Karyotype analysis and the DNA content measured by microfluorescence technique and expressed in fluorescence units.


RESULTS
The mean DNA content in cells from karyotypically normal and karyotypically abnormal myomas, respectively, was 37.4 +/- 6.9 and 30.4 +/- 1.8 fluorescence units in premenopausal females, 30.3 +/- 5.3 and 28.7 +/- 0.9 fluorescence units in menopausal females, and 31.6 +/- 2.7 and 32.9 +/- 5.8 fluorescence units in GnRH-a-treated females.


CONCLUSIONS
Forty percent of the myomas evaluated demonstrated an abnormal karyotype and had a significantly lower DNA content than the chromosomally normal myomas. After GnRH-agonist treatment, the DNA content was decreased in the euploid myoma group only.
Brosens
I
I
Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, Leuven, Belgium.
Johannisson
E
E
Dal Cin
P
P
Deprest
J
J
Van den Berghe
H
H
D001706:Biopsy; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D005453:Fluorescence; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007044:Hysterectomy; D007621:Karyotyping; D007889:Leiomyoma / Q000737:chemistry / Q000235:genetics* / Q000473:pathology; D008593:Menopause; D017697:Premenopause; D011446:Prospective Studies; D017329:Triptorelin Pamoate / Q000494:pharmacology*; D014594:Uterine Neoplasms / Q000737:chemistry / Q000235:genetics* / Q000473:pathology
D004273:DNA, Neoplasm; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone